The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Add Vildagliptin

Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%

DRUG

Add Glimepiride

Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%

Trial Locations (1)

135-710

Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Samsung Medical Center

OTHER